BioPhausia   Report issue

For profit Phase 2
Founded: Stockholm Sweden (1994)
Status: Acquired by Medivir (2011)

Organization Overview

First Clinical Trial
2003
NCT00199771
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2003

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Active Ingredients

Drugs in Phase 2 Trials (2)

dextran (1 trial)

sodium chloride (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Congenital Abnormalities (Phase 2)

Endocardial Cushion Defects (Phase 2)

Heart Defects, Congenital (Phase 2)

Heart Septal Defects (Phase 2)

Heart Septal Defects, Ventricular (Phase 2)

Transposition of Great Vessels (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 1
  • # of Trial APIs: 2